CD38 is highly and uniformly expressed on multiple myeloma (MM) cells, and at relatively
low levels on normal lymphoid and myeloid cells, and in some tissues of nonhematopoietic …

MM cells express high levels of CD38, while CD38 is expressed at relatively low levels on
normal lymphoid and myeloid cells, and in some non-hematopoietic tissues. This expression …

Background Isatuximab is an anti-CD38 monoclonal antibody approved in combination with
pomalidomide–dexamethasone and carfilzomib–dexamethasone for relapsed or refractory …

Background Isatuximab is a monoclonal antibody that binds a specific epitope on the human
CD38 receptor and has antitumour activity via multiple mechanisms of action. In a previous …

Background Anti-CD38 monoclonal antibodies have consistently shown increased efficacy
when added to standard of care for patients with multiple myeloma. We aimed to assess the …

Multiple myeloma (MM) is the second most common blood cancer. Treatments for MM
include corticosteroids, alkylating agents, anthracyclines, proteasome inhibitors …

CD 38 is a multifunctional cell surface protein that has receptor as well as enzyme functions.
The protein is generally expressed at low levels on various hematological and solid tissues …

Here we show that overexpression or activation of B-cell maturation antigen (BCMA) by its
ligand, a proliferation-inducing ligand (APRIL), promotes human multiple myeloma (MM) …

Emerging evidence suggests that FcγR-mediated cross-linking of tumor-bound mAbs may
induce signaling in tumor cells that contributes to their therapeutic activity. In this study, we …

Purpose: Knowledge about the mechanism of action (MoA) of monoclonal antibodies (mAb)
is required to understand which patients with multiple myeloma (MM) benefit the most from a …